KUALA LUMPUR, Jan 20 (Bernama) -- Adagene Inc (Adagene), a biotech company committed to transforming the discovery and development of novel antibody-based immunotherapies, has announced the appointment of David Gandara, M.D. to its Scientific and Strategic Advisory Board (the SAB).
“We are thrilled to welcome Dr Gandara to our SAB as a leading researcher and physician, as well as a thought leader in biomarker-driven strategies for lung cancer therapies,” said Co-Founder, Chief Executive Officer and Chairman of the Board of Adagene, Peter Luo, Ph.D. in a statement.
“We look forward to Dr Gandara’s insights, especially on the heels of the recently initiated trial in Singapore evaluating ADG106 in combination with Nivolumab in patients with advanced non-small cell lung cancer.”
Meanwhile, Dr Gandara commented: “I am delighted to join Adagene’s SAB at such an exciting time in the company's evolution. Adagene’s innovative antibody-based technology platform has the potential to advance the next generation of immuno-oncology treatments.
“I look forward to working alongside the impressive team to execute on the company’s mission to bring transformative new cancer therapeutics to patients around the world.”
Dr Gandara, Professor Emeritus and Senior Advisor of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center (UCDCCC), brings deep knowledge and understanding to the immuno-oncology field, and he is recognised for his translational research and clinical work in cancer drug and biomarker development.
Dr Gandara has received numerous awards, authored over 450 publications, and presented his work at meetings nationally and internationally. He is a co-leader at Lung MAP, a precision medicine umbrella clinical trial for the development of biomarker-driven strategies for new therapies in lung cancer.
Dr Gandara obtained his M.D. from University of Texas Medical Branch at Galveston, and he completed his clinical training as a resident at Madigan Army Medical Center, and as a Fellow in hematology and oncology at Letterman Army Medical Center.
More details at https://investor.adagene.com.
-- BERNAMA
No comments:
Post a Comment